Yes, Sanofi licensed from Kymab. There are a few groups targeting ICOS/ICOSL to modulate immune response to tumor (either alone or in combo with PD-1, CTLA-4, etc approaches previously mentioned on HN). Here's one reasonably recent backgrounder on rationale: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/
Still not clear that KY1044 really is the "experimental drug" mentioned in the linked BBC article, since as others have noted the article is pretty thin on detail.
Still not clear that KY1044 really is the "experimental drug" mentioned in the linked BBC article, since as others have noted the article is pretty thin on detail.